NEWSROOM | Galderma

We Are All Sculptra: first-of-its-kind Galderma initiative to demonstrate how everyone can benefit from Sculptra’s regenerative properties

Galderma expands Restylane® portfolio in Japan with launch of OBT™ hyaluronic acid injectables Restylane Defyne™ and Refyne™

Galderma announces U.S. FDA acceptance of RelabotulinumtoxinA Biologics License Application resubmission

Galderma tackles menopause-related skin changes with global survey and clinical trial inclusivity

Galderma unveils ‘Wake Up To Restylane’, underscoring Restylane as the ideal hyaluronic acid treatment for always-on natural beauty

IMCAS 2026: Galderma showcases the latest scientific advances behind the industry’s broadest injectable aesthetics portfolio

IMCAS 2026: Galderma’s scientific presentations

Galderma provides update on arbitration case regarding neuromodulator research and development partnership

TOXINS 2026: Clinical updates on Galderma’s leading neuromodulator portfolio further reinforce its leadership in Injectable Aesthetics

TOXINS 2026: Galderma’s scientific presentations

New published data confirms Nemluvio® (nemolizumab) can rapidly relieve itch and improve sleep in as early as two days in both atopic dermatitis and prurigo nodularis

Prurigo nodularis: a long road to diagnosis

Galderma announces first patient enrollment in study to assess nemolizumab in adults with Chronic Pruritus of Unknown Origin